NorthWest Biotherapeutics Inc (NWBO)

[VuBru]

Because they were prohibited from reporting secondary end-point results in their PR due to AHA embargo rules. They did talk about multiple SEs being robustly supportive of primary results (they could not use the word "significant"). The first SE tested in their sequential analysis is "hard MACE" (MI, death, stroke) which is more important than what they previously reported, and many peoplle assume they will fail on this endpoint. However, they are not allowed to test the next sequential SE unless the first SE (hard MACE) is significant, ergo, multiple SEs robustly supportive means at least that first two were significant. Their results will be stronger than anticipated and the price will go up.